Emerging Healthcare Solutions, Inc. (PinkSheets: EHSI) announced today that it has entered into an option agreement with OceanBASIS, a German company specializing in stem-cell and marine-collagen technologies and products.
During the 60-day option period, EHSI will conduct a due-diligence review of OceanBASIS and its prospects in order to negotiate a potential profit-sharing agreement. OceanBASIS is a biotech firm dedicated to developing and marketing sustainably derived marine natural products for the health and cosmetic industries. The company’s top projects under development include a bone scaffold designed for use as a stem cell matrix in cartilage repairing surgeries and a wound gel intended to improve healing of chronic wounds. Both products are derived from marine collagen, a purer form than the bovine collagen currently being used.
“OceanBASIS is working on the cutting edge of regenerative medicine, and we look forward to negotiating a definitive agreement with them soon,” said EHSI President and CEO Cindy Morrissey.
The burgeoning relationship between Emerging Healthcare Solutions and OceanBASIS is a result of EHSI’s recent efforts to expand its global reach, including the establishment of a business office in Frankfurt, Germany, in November that will allow EHSI to maintain long-term relationships with some of the world’s foremost stem cell researchers in Central and Western Europe.
Emerging Healthcare Solutions keeps a close eye on healthcare innovation worldwide, particularly in relation to stem cells. Last month, EHSI announced its acquisition of Panamanian biotech firm Celulas Genetica, a Central American leader in stem-cell technology acquisition and development. The company subsequently announced that Celulas Genetica will submit an international patent application for the Rutherford Procedure, a revolutionary new stem-cell treatment for liver disease licensed from the Chinese firm BBFITCL.
The Rutherford Procedure is being developed to use proton therapy to destroy scar-tissue cells in the liver using high-energy proton beams. As the scar tissue is systematically destroyed by the proton therapy, a catheter will deliver the patient’s own cultured stem cells directly to their liver through the bloodstream in the hope of regenerating the damaged, cirrhotic liver into a healthy, functioning organ once more.
EHSI invests in technology developed to compete in the stem-cell research industry alongside Amgen (NASDAQ:AMGN), Dendreon Corporation (NASDAQ:DNDN), Smith & Nephew (NYSE:SNN) and Pharmaceutical Product Development (NASDAQ:PPDI).
About Emerging Healthcare Solutions, Inc.
Emerging Healthcare Solutions, Inc. invests in and participates in the profits of emerging breakthrough medical technologies. The Company believes the secret of leveraging future value for its shareholders is the proper timing of its investment in promising new medical technologies. EHSI aims to capture future profits of promising new medical technologies by investing in these technologies at the inflection point of product development. We believe this model will deliver long-term positive results for our investors.
For more information, please visit http://www.EmergingHealthcareSolutionsInc.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.